AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT108.33-0.46 (-0.42%) ▼|ACN186.72-6.40 (-3.31%) ▼|ADBE266.51-19.24 (-6.73%) ▼|AMAT454.71+18.80 (+4.31%) ▲|AMD477.57+21.41 (+4.69%) ▲|AMGN437.23-6.89 (-1.55%) ▼|AMT175.85-1.90 (-1.07%) ▼|AMZN258.51-0.39 (-0.15%) ▼|AVGO357.90+0.74 (+0.21%) ▲|AXP326.16-3.66 (-1.11%) ▼|BA212.25+1.74 (+0.83%) ▲|BAC62.68-0.04 (-0.06%) ▼|BKNG193.29-1.84 (-0.94%) ▼|BLK1,122.29-3.86 (-0.34%) ▼|BMY66.82-1.27 (-1.87%) ▼|BNY164.84+0.51 (+0.31%) ▲|BRK-B506.03-2.10 (-0.41%) ▼|C137.72-0.42 (-0.30%) ▼|CAT813.94+13.80 (+1.72%) ▲|CL88.77-1.32 (-1.47%) ▼|CMCSA26.49-0.16 (-0.60%) ▼|COF219.60-0.90 (-0.41%) ▼|COP134.26-1.46 (-1.08%) ▼|COST915.74-9.67 (-1.04%) ▼|CRM259.23-5.20 (-1.97%) ▼|CSCO109.20+0.59 (+0.54%) ▲|CVS96.74-0.46 (-0.47%) ▼|CVX208.60-2.72 (-1.29%) ▼|DE693.53-0.88 (-0.13%) ▼|DHR207.66-3.37 (-1.60%) ▼|DIS105.31-1.85 (-1.73%) ▼|DUK120.22-1.18 (-0.97%) ▼|EMR152.82+2.61 (+1.74%) ▲|FDX322.52-1.79 (-0.55%) ▼|GD359.39-6.48 (-1.77%) ▼|GE337.12+3.64 (+1.09%) ▲|GEV941.95+0.11 (+0.01%) ▲|GILD151.00-0.23 (-0.15%) ▼|GM87.76+0.72 (+0.83%) ▲|GOOG335.31-3.77 (-1.11%) ▼|GOOGL338.46-3.80 (-1.11%) ▼|GS1,038.61+0.68 (+0.07%) ▲|HD321.05+2.98 (+0.94%) ▲|HON209.61+1.98 (+0.95%) ▲|IBM234.89+0.18 (+0.08%) ▲|INTC95.80+4.13 (+4.51%) ▲|INTU332.70-11.60 (-3.37%) ▼|ISRG366.70-3.13 (-0.85%) ▼|JNJ275.23-3.20 (-1.15%) ▼|JPM358.64-3.42 (-0.94%) ▼|KO88.07-0.74 (-0.83%) ▼|LIN477.57-4.62 (-0.96%) ▼|LLY1,149.36-10.24 (-0.88%) ▼|LMT525.28-7.67 (-1.44%) ▼|LOW204.45+2.55 (+1.26%) ▲|LRCX307.65+14.99 (+5.12%) ▲|MA579.21-6.50 (-1.11%) ▼|MCD255.69-3.94 (-1.52%) ▼|MDLZ61.28-0.17 (-0.28%) ▼|MDT94.17+1.07 (+1.15%) ▲|META616.77+6.09 (+1.00%) ▲|MMM168.56+0.25 (+0.15%) ▲|MO68.88-0.61 (-0.88%) ▼|MRK150.33-2.01 (-1.32%) ▼|MS217.72+0.57 (+0.26%) ▲|MSFT499.70-10.42 (-2.04%) ▼|MU1,016.59+58.43 (+6.10%) ▲|NEE83.43-0.63 (-0.75%) ▼|NFLX78.25-4.42 (-5.35%) ▼|NKE38.40-0.37 (-0.95%) ▼|NOW141.26-4.33 (-2.97%) ▼|NVDA230.36+1.91 (+0.84%) ▲|ORCL158.78+4.74 (+3.08%) ▲|PEP137.63-0.91 (-0.66%) ▼|PFE28.45-0.36 (-1.25%) ▼|PG146.44-0.48 (-0.33%) ▼|PLTR174.33-8.20 (-4.49%) ▼|PM182.53-3.64 (-1.96%) ▼|QCOM168.74+0.17 (+0.10%) ▲|RTX200.79-1.34 (-0.66%) ▼|SBUX104.47-1.35 (-1.28%) ▼|SCHW109.29-1.09 (-0.99%) ▼|SO88.11-0.66 (-0.74%) ▼|SPG209.44-2.08 (-0.98%) ▼|T25.68-0.51 (-1.95%) ▼|TMO613.78-4.65 (-0.75%) ▼|TMUS181.52-6.50 (-3.46%) ▼|TSLA354.08-22.29 (-5.92%) ▼|TXN258.44+4.61 (+1.82%) ▲|UBER75.76-0.20 (-0.26%) ▼|UNH397.14-3.80 (-0.95%) ▼|UNP289.62+0.47 (+0.16%) ▲|UPS102.29-1.21 (-1.17%) ▼|USB63.37-0.16 (-0.25%) ▼|V375.07-3.68 (-0.97%) ▼|VZ50.14-0.45 (-0.89%) ▼|WFC89.97+0.78 (+0.87%) ▲|WMT107.14-1.28 (-1.18%) ▼|XOM159.47-2.74 (-1.69%) ▼|
25.1 C
New York
Saturday, September 5, 2026

Tag: glucose

newssourceFORcompanyinformationcontent1releasesmarket

Zydus Wellness’ Glucon-D’s ‘Energy Ka Gola’ energizes thousands of children across India

~Distributed more than 700 kgs of Glucon-D infused Golas at 100+ stadiums and playgrounds, in Hyderabad, Kolkata, Lucknow, and Mumbai~~Launches film to help combat...

BloodVitals Pain-Free Blood Glucose Monitoring Device Launches to Support At-Home Wellness Tracking

Innovative needle-free technology empowers users to monitor glucose signals, oxygen saturation, and heart rate from home—without the discomfort or complexity of traditional tools. 
Innovative needle-free technology empowers users to monitor glucose signals, oxygen saturation, and heart rate from home—without the discomfort or complexity of traditional tools.

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog...

Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Stelo Files Complaint Against Dexcom, Inc. for Trademark Infringement, Negligence, Unfair Competition

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Stelo, an enterprise software company, has filed suit in Federal District Court for the Central District of California...

Cell Study by SDU and PKU Researchers Reveals Novel Mechanism to Regulate Glucose Metabolism

JINAN, China, June 23, 2025 /PRNewswire/ -- On May 29, 2025, Professor Sun Jinpeng's team and Professor Yu Xiao's team at Shandong University, collaborating with Professor...

Cell Study by SDU and PKU Researchers Reveals Novel Mechanism to Regulate Glucose Metabolism

JINAN, China, June 23, 2025 /PRNewswire/ -- On May 29, 2025, Professor Sun Jinpeng's team and Professor Yu Xiao's team at Shandong University, collaborating with Professor...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsGlucose

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers